Elizabeth Hurlburt - 18 Feb 2022 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role
EVP, Head of Clinical Ops.
Signature
/s/ Elizabeth Masson-Hurlburt
Issuer symbol
CRMD
Transactions as of
18 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 15:12:07 UTC
Previous filing
25 May 2021
Next filing
18 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CRMD Common Stock 8,000 18 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRMD Stock Option (Right to Buy Common Stock) Award $0 +100,000 $0.000000 100,000 18 Feb 2022 Common Stock 100,000 $4.03 Direct F6
holding CRMD Stock Option (Right to Buy Common Stock) 140,000 18 Feb 2022 Common Stock 140,000 $8.32 Direct F1
holding CRMD Stock Option (Right to Buy Common Stock) 37,500 18 Feb 2022 Common Stock 37,500 $5.63 Direct F2
holding CRMD Stock Option (Right to Buy Common Stock) 37,500 18 Feb 2022 Common Stock 37,500 $4.08 Direct F2
holding CRMD Stock Option (Right to Buy Common Stock) 24,764 18 Feb 2022 Common Stock 24,764 $5.63 Direct F3
holding CRMD Stock Option (Right to Buy Common Stock) 20,880 18 Feb 2022 Common Stock 20,880 $8.30 Direct F4
holding CRMD Stock Option (Right to Buy Common Stock) 54,000 18 Feb 2022 Common Stock 54,000 $1.45 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones.
F2 These options were granted on 05/11/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F3 These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F4 These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. These options include options to purchase 2,100 shares that are subject to vesting each on January 10, 2021 and January 10, 2022.
F5 The options vest as follows: 37,200 will vest over four years in four (4) equal installments on the first four anniversaries of 3/19/2018. The remaining options vest on the achievement of certain milestones, subject to continued employment.
F6 These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

Remarks:

The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.